August 2023 Snap Recap: Chemo Shortages, FDA Approvals in Multiple Myeloma
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Looking back at August 2023, several news items proved to be the most poured over by CancerNetwork® readers. This included 2 FDA approvals for patients with relapsed/refractory multiple myeloma, solutions for patients with breast cancer to conceive a child mid-treatment, details of the ongoing chemotherapy shortage, and a continuation of conversations from July’s Sarcoma Awareness Month.1-6
Full versions of the articles are referenced below in the order that they appear:
- FDA Gives Talquetamab Accelerated Approval for R/R Multiple Myeloma by Ariana Pelosci
- Elranatamab Receives Accelerated Approval in R/R Multiple Myeloma by Ariana Pelosci
- Endocrine Therapy Break May Allow for Conception in HR+ Breast Cancer by Ariana Pelosci
- Pharmacy Expert Details Causes of Carboplatin/Cisplatin Shortage in the U.S. by Michael Ganio, PharmD, MS, BCPS, FASHP
- Expert Highlights ‘Exciting’ Ongoing Trials in Different Sarcoma Subtypes by Brian Van Tine, MD, PhD
References
- U.S. FDA approved TALVEY (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma. News release. The Janssen Pharmaceuticals. August 10, 2023. Accessed September 14, 2023. https://prn.to/3KwnjyD
- Pfizer’s Elrexfio receives U.S. FDA accelerated approval for relapsed or refractory multiple myeloma. News release. Pfizer. August 14, 2023. Accessed September 14, 2023. https://bit.ly/3DTCRIY
- Partridge AH, Niman SM, Ruggeri M, et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645-1656. doi:10.1056/NEJMoa2212856
- NCCN releases statement addressing ongoing chemotherapy shortages; shares survey results finding more than 90% of cancer centers are impacted. News release. National Comprehensive Cancer Network. June 7, 2023. Accessed September 14, 2023. https://shorturl.at/ERY27
- Ingham M, Blay JY, Baird J, et al. A phase II/III study evaluating the efficacy and safety of unesbulin in advanced leiomyosarcoma (SUNRISELMS). Ann Oncol. 2022;33(7):S1243-S1244. doi:10.1016/j.annonc.2022.07.1917
- Hong DS, Van Tine BA, Biswas S, et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat Med. 2023;29:104-114. doi:10.1038/s41591-022-02128-z
Related Videos
Related Content
